Calculation of disease RR
. | Calculation by Sokal et al24 . | Calculation by Hasford et al25 . |
|---|---|---|
| Age | 0.116 × (age - 43.4) | 0.666 when age ≥ 50 y |
| Spleen* | 0.0345 × (spleen - 7.51) | 0.042 × spleen |
| Platelet count, × 109/L | 0.188 × [(platelet count ÷ 700)2 - 0.563] | 1.0956 when platelet count ≥ 1500 × 109/L |
| Blood myeloblasts, % | 0.0887 × (myeloblasts - 2.10) | 0.0584 × myeloblasts |
| Blood basophils, % | NA | 0.20399 when basophils > 3% |
| Blood eosinophils, % | NA | 0.0413 × eosinophils |
| Relative risk† | ||
| Low | < 0.8 | ≤ 780 |
| Intermediate | 0.8-1.2 | 781-1480 |
| High | > 1.2 | > 1480 |
. | Calculation by Sokal et al24 . | Calculation by Hasford et al25 . |
|---|---|---|
| Age | 0.116 × (age - 43.4) | 0.666 when age ≥ 50 y |
| Spleen* | 0.0345 × (spleen - 7.51) | 0.042 × spleen |
| Platelet count, × 109/L | 0.188 × [(platelet count ÷ 700)2 - 0.563] | 1.0956 when platelet count ≥ 1500 × 109/L |
| Blood myeloblasts, % | 0.0887 × (myeloblasts - 2.10) | 0.0584 × myeloblasts |
| Blood basophils, % | NA | 0.20399 when basophils > 3% |
| Blood eosinophils, % | NA | 0.0413 × eosinophils |
| Relative risk† | ||
| Low | < 0.8 | ≤ 780 |
| Intermediate | 0.8-1.2 | 781-1480 |
| High | > 1.2 | > 1480 |
Risk according to Sokal et al24 was defined based on patients treated with conventional chemotherapy. Risk according to Hasford et al25 was defined based on patients treated with rIFNα-based regimens. We emphasize that calculation of the risk requires use of clinical and hematologic data at diagnosis, prior to any treatment.
NA indicates not applicable.
Centimeters below costal margin, maximum distance.
Relative risk for the Sokal calculation is expressed as exponential of the total; that for the Hasford calculation is expressed as the total × 1000.